
The FDA has taken the decision to authorise the use of Novartis’ Egaten (triclabendazole) in patients older than six years …
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand

